25 July 2022

Amedeo Smart

Independent Medical Education

Subscriber: th..@boehringer-ingelheim.com

HIV Infection

25 July 2022 | n=48

  1. Peluso MJ, Spinelli MA, Deveau TM, Forman CA, et al.
    Post-acute sequelae and adaptive immune responses in people living with HIV recovering from SARS-COV-2 infection.
    AIDS 2022.

  2. Zhao B, Ding H, Song W, Kang M, et al.
    Antiretroviral therapy initiation within 7 days and 8 days-30 days post-HIV diagnosis demonstrates similar benefits in resource-limited settings.
    AIDS 2022.

  3. Michel M, Labenz C, Wahl A, Anders M, et al.
    Prevalence and risk factors of non-alcoholic steatohepatitis with significant fibrosis in people living with HIV.
    AIDS 2022.

  4. Hunt M, Mcniff MM, Vincent AE, Sabin C, et al.
    Skeletal muscle mitochondrial dysfunction in contemporary antiretroviral therapy: a single cell analysis.
    AIDS 2022.

  5. Rai MA, Shi V, Kennedy BD, Whitehead EJ, et al.
    Effect of aging on immune cells in male HIV-infected and -uninfected healthy individuals.
    AIDS 2022.

  6. Hau TTT, Nishizawa M, Harada S, Phan MH, et al.
    Association of envelope-specific B-cell differentiation and viral selective pressure signatures in HIV-1 CRF01_AE infection.
    AIDS 2022.

  7. Ante-Testard PA, Hamidouche M, Apouey B, Baggaley R, et al.
    Understanding the pathways leading to socioeconomic inequalities in HIV testing uptake in 18 sub-Saharan African countries: a mediation analysis.
    AIDS 2022.

  8. Girardi E, Caro-Vega Y, Cozzi-Lepri A, Musaazi J, et al.
    The contribution of late HIV diagnosis on the occurrence of HIV-associated tuberculosis: a 5-year estimate using real-world data.
    AIDS 2022.

  9. Hansen ME, Mangusan R, Lurain K, Odeny T, et al.
    Characteristics of patients admitted to the intensive care unit with Kaposi sarcoma herpesvirus-associated diseases.
    AIDS 2022.

  10. Rousset S, Zenou M, Saunier A, Varenne F, et al.
    Immune recovery-related patterns of post kala-azar dermal and ocular leishmaniasis in people living with HIV: a national survey and literature review.
    AIDS 2022.

  11. Fotso AS, Johnson C, Vautier A, Kouame KB, et al.
    Routine programmatic data show a positive population-level impact of HIV self-testing: the case of Cote d'Ivoire and implications for implementation.
    AIDS 2022.

  12. Teng AE, Kennedy KF, Parikh RV, Armstrong EJ, et al.
    Temporal trends and outcomes of peripheral artery disease revascularization and amputation among the HIV population.
    AIDS 2022.

  13. Weiser B, Shi B, Kemal K, Burger H, et al.
    Long-term antiretroviral therapy mitigates mortality and morbidity independent of HIV tropism: 18 years follow-up in a women's cohort.
    AIDS 2022.

  14. Mungwira RG, Laurens MB, Nyangulu W, Divala TH, et al.
    High burden of malaria among Malawian adults on antiretroviral therapy after discontinuing prophylaxis.
    AIDS 2022.

  15. Bannister WP, Mast TC, de Wit S, Gerstoft J, et al.
    Changes in body mass index and clinical outcomes after initiation of contemporary antiretroviral regimens.
    AIDS 2022.

  16. Zhu W, Huang YA, Weiner J, Neblett-Fanfair R, et al.
    Impact of the COVID-19 pandemic on prescriptions for antiretroviral drugs for HIV treatment in the United States, 2019-2021.
    AIDS 2022.

  17. Li G, Park LS, Lodi S, Logan RW, et al.
    Tenofovir disoproxil fumarate and COVID-19 outcomes in men with HIV.
    AIDS 2022.

  18. Tincati C, Ficara M, Ferrari F, Augello M, et al.
    Gut-dependent inflammation and alterations of the intestinal microbiota in individuals with perinatal HIV exposure and different HIV serostatus.
    AIDS 2022.

  19. Panneer N, Balaji AB, Crim SM, Bosh KA, et al.
    Assessing concordance of HIV risk behaviors collected by different surveillance systems.
    AIDS 2022.

  20. Vakili S, Paneru B, Guerrier CM, Miller J, et al.
    Altered adipose tissue macrophage populations in people with HIV on integrase inhibitor-containing ART.
    AIDS 2022.

  21. Huik K, Hill S, George J, Pau A, et al.
    High-level dolutegravir resistance can emerge rapidly from few variants and spread by recombination: implications for INSTI salvage therapy.
    AIDS 2022.

  22. Mican R, Grela AG, Cadinanos J, de Miguel R, et al.
    Impact of Pre-Existing Nrti Resistance on the Effectiveness of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment Experience Patients: Real-World Data.
    AIDS 2022.

  23. Neary J, Mugo C, Wagner A, Ogweno V, et al.
    Caregiver fears and assumptions about child HIV status drive not testing children for HIV.
    AIDS 2022;36:1323-1325.

  24. Bottanelli M, Messina E, Barbera M, Guffanti M, et al.
    Challenging management of a post-coronavirus disease 2019 invasive Aspergillus sinusitis in a person living with HIV.
    AIDS 2022;36:1321-1323.

  25. Gianserra L, Dona MG, Giuliani E, Stingone C, et al.
    High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV - but HIV viremia matters?
    AIDS 2022;36:1319-1320.

  26. Woldemeskel BA, Karaba AH, Garliss CC, Beck EJ, et al.
    Decay of coronavirus disease 2019 mRNA vaccine-induced immunity in people with HIV.
    AIDS 2022;36:1315-1317.

  27. Rinaldo CR.
    Cytomegalovirus: 40 years and still the major viral cofactor in HIV infection.
    AIDS 2022;36:1311-1313.

  28. Poli G, Stapleton JT.
    Sex matters... cytokines and disease progression in men and women receiving combination antiretroviral therapy.
    AIDS 2022;36:1307-1309.

  29. Crum NF, Ahmad A.
    Immunity against measles in people with HIV: the need for more research and surveillance.
    AIDS 2022;36:1305-1306.

  30. Stover S, Milloy MJ, Grant C, Fairbairn N, et al.
    Estimating the minimum antiretroviral adherence required for plasma HIV-1 RNA viral load suppression among people living with HIV who use unregulated drugs.
    AIDS 2022;36:1233-1243.

  31. Casseb J, Lopes LR.
    Reflection about the ancient emergence of HTLV-2 infection: Potential for endogenization.
    AIDS Res Hum Retroviruses 2022.

  32. Chang C, Agbaji O, Mitruka K, Olatunde B, et al.
    Clinical Outcomes in a Randomized Controlled Trial Comparing Point-of-Care Versus Standard HIV Viral Load Monitoring in Nigeria.
    Clin Infect Dis 2022.

  33. Sekaggya-Wiltshire C, Nabisere R, Musaazi J, Otaalo B, et al.
    Decreased dolutegravir and efavirenz concentrations with preserved virological suppression in patients with TB and HIV receiving high-dose rifampicin.
    Clin Infect Dis 2022.

  34. Levin AE, Bangdiwala AS, Nalintya E, Kagimu E, et al.
    Outpatient Cryptococcal Antigen Screening is Associated with Favorable Baseline Characteristics and Improved Survival in Persons with Cryptococcal Meningitis in Uganda.
    Clin Infect Dis 2022.

  35. Tieosapjaroen W, Fairley CK, Eric CPF, Ivette A, et al.
    Preferences for weight gain compared with other antiretroviral therapy side effects in people living with HIV: a discrete choice experiment.
    J Acquir Immune Defic Syndr 2022.

  36. Wendt CH, Samorodnitsky S, Lock EF, Kruk M, et al.
    The lung and plasma metabolome in HIV-associated obstructive lung disease (OLD).
    J Acquir Immune Defic Syndr 2022.

  37. Brown LK, Baltrusaitis K, Kennard BD, Emslie GJ, et al.
    Forty-eight Week Outcomes of a Site-Randomized Trial of Combined Cognitive Behavioral Therapy and Medication Management Algorithm for Treatment of Depression Among Youth with HIV in the United States.
    J Acquir Immune Defic Syndr 2022.

  38. Toribio M, Wilks MQ, Hedgire S, Lu MT, et al.
    Increased Macrophage-Specific Arterial Infiltration Relates to Non-calcified Plaque and Systemic Immune Activation in People with HIV.
    J Infect Dis 2022.

  39. Mahant A, Guerguis S, Blevins TP, Cheshenko N, et al.
    Herpes Simplex Virus Glycoprotein D Antibodies Fail to Elicit Antibody-Dependent Cell-Mediated Cytotoxicity: Implications for Future Vaccines.
    J Infect Dis 2022.

  40. Lan J, Li W, Yu R, Syed F, et al.
    Cell-to-cell transmission of HIV-1 from provirus-activated cells to resting naive and memory human primary CD4 T cells is highly efficient and requires CD4 and F-actin but not chemokine receptors.
    J Med Virol 2022.

  41. Macedo AB, Levinger C, Nguyen BN, Richard J, et al.
    The HIV Latency Reversal Agent HODHBt Enhances NK Cell Effector and Memory-Like Functions by Increasing Interleukin-15-Mediated STAT Activation.
    J Virol 2022.

  42. Baker EJ, Hughes K, Travieso T, Klotman ME, et al.
    Establishment, Persistence, and Reactivation of Latent HIV-1 Infection in Renal Epithelial Cells.
    J Virol 2022.

  43. Ratcliff AN, Venner CM, Olabode AS, Knapp J, et al.
    Enhancement of CD4 Binding, Host Cell Entry, and Sensitivity to CD4bs Antibody Inhibition Conferred by a Natural but Rare Polymorphism in the HIV-1 Envelope.
    J Virol 2022.

  44. Wietgrefe SW, Duan L, Anderson J, Marques G, et al.
    Detecting Sources of Immune Activation and Viral Rebound in HIV Infection.
    J Virol 2022.

  45. .
    Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020.
    Lancet 2022;400:185-235.

  46. Booth A.
    New HIV law welcomed in Argentina.
    Lancet 2022;400:149.

  47. Thornhill JP, Barkati S, Walmsley S, Rockstroh J, et al.
    Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022.
    N Engl J Med 2022.

  48. Zhang H, Deng T, Fang Q, Li S, et al.
    Endodomain truncation of the HIV-1 envelope protein improves the packaging efficiency of pseudoviruses.
    Virology 2022;574:1-8.

Display articles in

Amedeo HIV Infection

Data Origin

You selected the following journals for your Amedeo HIV Infection newsletter:

AIDS, AIDS Res Hum Retroviruses, Ann Intern Med, BMJ, Clin Infect Dis, J Acquir Immune Defic Syndr, J Clin Immunol, J Clin Invest, J Infect Dis, J Med Virol, J Virol, JAMA, Lancet, N Engl J Med, Nat Med, Pediatr Infect Dis J, Science, Virology.

To modify the journal selection, please open your Newsletter Management Page. If you don't remember the URL, please submit the email address of your Amedeo subscription.

Your email:

Amedeo HIV Infection

Five-Week Literature

03 October 2022

26 September 2022

19 September 2022

12 September 2022

05 September 2022

25 July 2022

Multidisciplinary Journal Club

  1. Wu YW, Comstock BA, Gonzalez FF, Mayock DE, et al.
    Trial of Erythropoietin for Hypoxic-Ischemic Encephalopathy in Newborns.
    N Engl J Med. 2022;387:148-159.

  2. Ansell SM, Radford J, Connors JM, Dlugosz-Danecka M, et al.
    Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.
    N Engl J Med. 2022 Jul 13. doi: 10.1056/NEJMoa2206125.

  3. Mitchell PJ, Yan B, Churilov L, Dowling RJ, et al.
    Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4.5 h of stroke onset: an open-label, blinded-endpoint, randomised non-inferiority trial.
    Lancet. 2022;400:116-125.

Every week, Amedeo's Multidisciplinary Journal Club (MJC) presents a selection of outstanding articles. Take a look beyond the horizon.

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016